McBroom & Associates LLC Grows Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

McBroom & Associates LLC increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,540 shares of the medical equipment provider’s stock after buying an additional 132 shares during the quarter. Intuitive Surgical comprises 5.6% of McBroom & Associates LLC’s portfolio, making the stock its 5th largest holding. McBroom & Associates LLC’s holdings in Intuitive Surgical were worth $9,108,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Mirador Capital Partners LP raised its position in shares of Intuitive Surgical by 1.4% during the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock worth $1,732,000 after buying an additional 50 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after purchasing an additional 1,129 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Intuitive Surgical by 617.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after purchasing an additional 76,649 shares during the period. Brookstone Capital Management boosted its stake in Intuitive Surgical by 22.4% during the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock valued at $5,340,000 after purchasing an additional 2,289 shares in the last quarter. Finally, M&G Plc increased its position in shares of Intuitive Surgical by 53.5% during the 2nd quarter. M&G Plc now owns 5,069 shares of the medical equipment provider’s stock valued at $2,256,000 after purchasing an additional 1,766 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ISRG. Leerink Partners upped their price objective on Intuitive Surgical from $489.00 to $502.00 in a report on Thursday. Wells Fargo & Company boosted their price target on shares of Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a research report on Friday. Truist Financial raised their price objective on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Piper Sandler reiterated an “overweight” rating and issued a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a report on Friday. Finally, BTIG Research set a $535.00 target price on shares of Intuitive Surgical in a research note on Friday. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $513.74.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $446.60, for a total value of $167,921.60. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,458,979.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Robert Desantis sold 376 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $446.60, for a total transaction of $167,921.60. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,458,979.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Trading Up 10.0 %

Shares of ISRG stock opened at $521.15 on Friday. The company has a market capitalization of $184.85 billion, a price-to-earnings ratio of 94.07, a P/E/G ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $523.34. The stock’s fifty day simple moving average is $483.85 and its 200-day simple moving average is $438.17.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.18 EPS. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.